WuXi Biologics announced that the company has won the operations category of the 2023 Facility of the Year Award (FOYA) from the International Society for Pharmaceutical Engineering (ISPE).

In its production site in Dundalk, Ireland, the company was honoured for adopting creative solutions while adhering to legal standards, overcoming unanticipated challenges, and maintaining project success and product safety.

The facility is one of the biggest of its kind in Europe, with two manufacturing sections using 6x1KL single-use bioreactors for perfusion and 12x4KL single-use bioreactors for fed-batch.

Chris Chen, CEO of WuXi Biologics, said, "We are very proud to be recognized by ISPE for the second time. Receiving the FOYA award in the Operations category validates our Global Dual Sourcing strategy, leading technology platform, and excellent execution, and will motivate us to continue striving for the highest level of service to enable our global partners for the benefit of patients worldwide."
 

The plant received its first GMP certificate from the Irish Health Products Regulatory Authority (HPRA) nine months after it began operations. Sustainable practises, such as conserving energy and recycling materials, are incorporated into the building and operation of the facility in accordance with WuXi Biologic’s Environmental, Social, and Governance (ESG) strategy. At the time being, Ireland's site receives all of its energy from renewable sources.